SCHEMBL14770547

SCHEMBL14770547

CCOc1ccc2[nH]c(C(C)c3ccc(OCc4cc(F)ccc4F)c(Cl)c3)nc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1C Q13936 1/20 0.43
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
HTT P42858 1/20 0.39
MRGPRX4 Q96LA9 1/20 0.34
POLB P06746 2/20 0.33
ALDH1A1 P00352 2/20 0.32
HTR2A P28223 2/20 0.32
SLC6A4 P31645 2/20 0.32
KCNH2 Q12809 2/20 0.32
HPGD P15428 1/20 0.32
IDO1 P14902 2/20 0.32
LMNA P02545 2/20 0.32
GAA P10253 1/20 0.32
MAPT P10636 1/20 0.32
BRD4 O60885 1/20 0.32
KDM4C Q9H3R0 1/20 0.32
PDE4B Q07343 1/20 0.31
PKM P14618 1/20 0.31
CNR2 P34972 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14770545 0.90 CACNA1C (0.44) CACNA1CMEN1KMT2AHTTPOLB
SCHEMBL12065314 0.90 CACNA1C (0.42) CACNA1CMEN1KMT2AHTTMRGPRX4
SCHEMBL14770526 0.88 CACNA1C (0.48) CACNA1CMEN1KMT2AHTTPOLB
SCHEMBL12066067 0.82 CACNA1C (0.46) CACNA1CMEN1KMT2AHTTPOLB
SCHEMBL14770527 0.82 CACNA1C (0.38) CACNA1CMEN1KMT2APOLBHTR2A
SCHEMBL12065289 0.81 CACNA1C (0.46) CACNA1CMEN1KMT2AHTTPOLB
SCHEMBL14770531 0.81 CACNA1C (0.40) CACNA1CMEN1KMT2AHTTPOLB
SCHEMBL14770546 0.81 CACNA1C (0.45) CACNA1CMEN1KMT2AHTTPOLB
SCHEMBL14770598 0.81 KMT2A (0.43) CACNA1CMEN1KMT2AHTTPOLB
SCHEMBL12065305 0.80 CACNA1C (0.43) CACNA1CMEN1KMT2AHTTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 US disclosed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE CACNA1E, CACNA1G, CACNA1A CACNA1C 16/4885MEN1 2676/4885KMT2A 4545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.